Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Enrollment opens in phase IIa study of MK-1942 in treatment-resistant depression

May 5, 2021

LRRK2 inhibitor DNL-151 well tolerated in healthy volunteers and patients with PD

May 4, 2021

Promising part A data from MOMENTUM study of SRP-5051 in DMD

May 4, 2021

New model allows exploration of PHF21B gene function

May 4, 2021

Heptares Therapeutics presents EP4 receptor antagonists

May 3, 2021

Esteve Pharmaceuticals patents new analgesics

May 3, 2021

Janssen Pharmaceutica divulges CB1 and/or CB2 receptor agonists

May 3, 2021

FDA clears IND application for PF-614-MPAR opioid with overdose protection

May 3, 2021

Characterization of HSK-16149, a selective ligand of VGCC alpha2delta subunit

May 3, 2021

Atogepant statistically reduces monthly migraine days in phase III trial

April 30, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...